Metyas Samy, Tomassian Christopher, Messiah Ramy, Gettas Tina, Chen Christina, Quismorio Anne
University of Southern California, CA 91722, United States.
Covina Arthritis Clinic, Covina, CA, United States.
Curr Rheumatol Rev. 2019;15(3):234-237. doi: 10.2174/1573397115666181130094455.
Psoriasis is a chronic immune-medicated inflammatory condition that affects 2-3% of the population, which can lead to psoriatic arthritis. There are multiple regimens for the treatment of psoriasis including disease- modifying anti rheumatic drugs (DMARDS) and biologic agent, phototherapy and apremilast. While monotherapy with biologic agents is effective for many patients with psoriasis some patients are not satisfied by the outcome and require combination therapy. No data exist on the safety of apremilast as a component of combination therapy with biological therapies.
The aim of the study was to determine the safety of apremilast in combination of biologic therapies in the treatment of plaque psoriasis and psoriatic arthritis.
This was retrospective study, open label study carried out at a single community Rheumatology center. Twenty-two patients diagnosed with plaque psoriasis and psoriatic arthritis according to American college of Rheumatology criteria-participated. Apremilast was added to their current biologic agent. Patients were permitted to their current biologic treatment.
Out of 22 patients, six patients developed side effects, none of which caused discontinuation of therapy. Out of the six patients who developed side effects, two patients developed nausea and two patients developed diarrhea. One patient developed weight loss and one patient developed abdominal pain.
Apremilast can be safely combined with all biologic agents in patients with plaque psoriasis or psoriatic arthritis not responding adequately to biologics alone.
银屑病是一种慢性免疫介导的炎症性疾病，影响2%-3%的人口，可导致银屑病关节炎。银屑病的治疗有多种方案，包括改善病情抗风湿药（DMARDs）、生物制剂、光疗和阿普米司特。虽然生物制剂单药治疗对许多银屑病患者有效，但一些患者对治疗结果不满意，需要联合治疗。目前尚无关于阿普米司特作为生物疗法联合治疗组成部分的安全性数据。
本研究的目的是确定阿普米司特联合生物疗法治疗斑块状银屑病和银屑病关节炎的安全性。
这是一项在单一社区风湿病中心进行的回顾性、开放标签研究。22例根据美国风湿病学会标准诊断为斑块状银屑病和银屑病关节炎的患者参与了研究。在他们当前使用的生物制剂中添加阿普米司特。患者继续接受他们当前的生物治疗。
22例患者中，6例出现副作用，但均未导致治疗中断。在出现副作用的6例患者中，2例出现恶心，2例出现腹泻。1例出现体重减轻，1例出现腹痛。
对于单独使用生物制剂治疗效果不佳的斑块状银屑病或银屑病关节炎患者，阿普米司特可安全地与所有生物制剂联合使用。
